Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Surgical Attrition in Resectable NSCLC: Risk Factors, Patient Communication, and Strategies to Optimize Continuity of Care

August 5th 2025

Panelists discuss how neoadjuvant chemoimmunotherapy maintains acceptable surgical safety profiles with mortality rates under 4% and how technical complexity primarily stems from hilar lymph node involvement rather than the systemic therapy itself, requiring experienced surgeons to handle these cases.

Guideline Updates and Trial Data Solidify the Role of HER2/MET IHC Testing in NSCLC: With Martin F. Dietrich, MD, PhD

August 4th 2025

Dr Dietrich discusses the rationale for testing for HER2 and MET mutations in patients with NSCLC, as well as best practices for implementing this testing.

Molecular Testing in Lung Cancer: Personalized Diagnostics Are Transforming Care

August 4th 2025

Luis E. Raez, MD, FACP, FASCO, dives into evolving practices in molecular testing for patients with lung cancer.

Five Under 5: Top Oncology Videos for the Week of 7/27

August 3rd 2025

The top 5 OncLive videos of the week cover insights in lung cancer, myelofibrosis, and mantle cell lymphoma.

The OncFive: Top Oncology Articles for the Week of 7/27

August 2nd 2025

Perioperative durvalumab sBLA gets priority review in gastric/GEJ cancer, acalabrutinib combination sNDA under review in CLL, and more.

VT3989 Receives FDA Orphan Drug Designation for Mesothelioma

August 1st 2025

The first-in-class TEAD autopalmitoylation inhibitor VT3989 has received FDA orphan drug designation for the treatment of patients with mesothelioma.

OncLive’s July Roundup of Key FDA Approvals in Oncology: 4 Decisions to Know

August 1st 2025

Here is your guide to all therapeutic options that were approved by the FDA in July 2025 spanning tumor types.

Dr Pelz on the Role of Minimally Invasive Surgical Techniques in Lung Cancer

August 1st 2025

Geoffrey B. Pelz, MD, discusses the role of minimally invasive surgical approaches for the treatment of patients with lung cancer.

Minimally Invasive Surgery and Multidisciplinary Collaboration Improve Recovery Time in Lung Cancer

August 1st 2025

Geoffrey B. Pelz, MD, discusses the evolution of thoracic surgical oncology, along with newer minimally invasive approaches to surgery in lung cancer.

China’s NMPA Accepts sNDA for Ivonescimab Plus Chemotherapy in Frontline Advanced Squamous NSCLC

July 31st 2025

Ivonescimab plus chemotherapy is under review in China for the frontline treatment of patients with advanced squamous non–small cell lung cancer.

Frontline IMM2510 Plus Chemo Drives Responses in Advanced NSCLC

July 31st 2025

IMM2510 plus chemotherapy generated responses in the first-line treatment of advanced non–small cell lung cancer.

Revisit Every OncLive On Air Episode From July 2025

July 31st 2025

Read a recap of the episodes of OncLive On Air that debuted in July 2025.

Dr Salgia on Biomarker-Driven Therapies of Interest for Second-Line SCLC

July 30th 2025

Ravi Salgia, MD, PhD, highlights biomarker-driven strategies in development for second-line small cell lung cancer management.

Dr Kim on the Collaborative, Forward-Thinking Nature of the 2025 BTG in Lung Cancer Meeting

July 30th 2025

Edward S. Kim, MD, MBA, highlighted the distinct purpose of the Bridging the Gaps in Lung Cancer consensus meeting.

FDA Grants Fast Track Designation to Ateganosine for NSCLC

July 30th 2025

The FDA has granted fast track designation to ateganosine for non–small cell lung cancer.

Dr Sen on the Role of Immunotherapy in SCLC

July 30th 2025

Triparna Sen, PhD, discusses the role of immunotherapy for the treatment of patients with small cell lung cancer.

Dr Florez on the Importance of Establishing Consensus Within the Evolving Lung Cancer Treatment Landscape

July 30th 2025

Narjust Florez, MD discusses the importance of establishing expert consensus in the evolving lung cancer treatment landscape in 2025.

Clinical Utility of ctDNA in Guiding Perioperative Treatment Decisions in Early-Stage NSCLC

July 29th 2025

Panelists discuss how circulating tumor DNA (ctDNA) serves as a promising biomarker for identifying patients at higher risk who may benefit from therapy escalation, though they acknowledge the current lack of prospective data on how to act therapeutically on positive ctDNA results.

Optimizing Adjuvant Therapy Decisions in Resectable NSCLC: Integrating Pathologic Response, PD-L1, and Nodal Status

July 29th 2025

Panelists discuss how treatment decisions should integrate multiple factors, including pathologic complete response (pCR), PD-L1 status, and nodal involvement, with particular emphasis on continuing adjuvant therapy for N2 disease and non-PCR patients despite the complexity of using residual viable tumor as a decision-making tool.

Knowledge of Unique ADC-Related Toxicities Is Critical for Safe, Effective Use in NSCLC

July 28th 2025

Corey J. Langer, MD, FACP, provides a focused overview of antibody-drug conjugate–related toxicities and AE management in lung cancer.